Mesenchymal stromal cells: a promising cell source for the treatment of inflammatory cardiomyopathy.

C Tschöpe, K Miteva, H-P Schultheiss, S Van Linthout

Department of Cardiology & Pneumology, Charité-University Medicine, Berlin Campus, Benjamin Franklin Hindenburgdamm 30, 12200 Berlin. carsten.tschoepe@charite.de

Current pharmaceutical design 2011 Oct

filter terms:

Inflammatory cardiomyopathy is associated with a diffuse inflammation in the heart accompanied with cardiac fibrosis, cardiomyocyte apoptosis, and reduced capillary density. On the other hand, mesenchymal stromal cells (MSCs) have immunomodulatory, anti-fibrotic, anti-apoptotic, and pro-angiogenic features, making them attractive candidates for the treatment of inflammatory cardiomyopathy. The potential of MSC application for the treatment of myocarditis is supported by their beneficial effects in experimental models of acute and chronic inflammatory cardiomopathy. This review summarizes the cardioprotective features of MSCs and describes how MSCs are primed by the inflammatory environment to exert their protective effects. In view of clinical translation, searching for the optimal source of MSC and delivery route, allowing efficient and non-invasive cell application, the differences between MSCs of distinct origin and between diverse routes of application are outlined.

Citation

C Tschöpe, K Miteva, H-P Schultheiss, S Van Linthout. Mesenchymal stromal cells: a promising cell source for the treatment of inflammatory cardiomyopathy. Current pharmaceutical design. 2011 Oct;17(30):3295-307